Drug Profile
Sovleplenib - HUTCHMED
Alternative Names: HMPL-523; HMPL-523 acetateLatest Information Update: 26 Mar 2024
Price :
$50
*
At a glance
- Originator Hutchison MediPharma
- Developer Hutchison MediPharma; HUTCHMED
- Class Amines; Anti-inflammatories; Antineoplastics; Antirheumatics; Morpholines; Piperidines; Pyrazines; Pyridones; Small molecules; Sulfones
- Mechanism of Action Syk kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preregistration Idiopathic thrombocytopenic purpura
- Phase II/III Autoimmune haemolytic anaemia
- Phase I B-cell lymphoma; Non-Hodgkin's lymphoma; Unspecified
- No development reported Acute myeloid leukaemia; Chronic lymphocytic leukaemia
- Discontinued Haematological malignancies; Lupus vulgaris; Multiple sclerosis; Rheumatoid arthritis
Most Recent Events
- 22 Mar 2024 HUTCHMED announces intention to submit NDA for Antibody autoimmune hemolytic anaemia in China
- 01 Mar 2024 Phase I development is ongoing US, Finland, France, Italy, Spain and Poland
- 28 Feb 2024 HUTCHMED plans to initiate a dose-finding study in Immune thrombocytopenia purpura (ITP) in the U.S./EU in mid-2024